S&P 500 Futures: Tests 3,500 after Pharmamar says Aplidin drug is enormously promising in treating COVID-19

Dhwani Mehta FXStreet

With the global COVID-19 count topping 40 million, amid the latest surge in the European coronavirus cases, Spanish pharmaceutical company PharmaMar came out with a piece of welcome news, citing that its cancer drug - Aplidin is enormously promising in treating COVID-19.

This comes after the Spanish pharma giant said Friday, a clinical trial of its cancer drug Aplidin to treat adult patients with COVID-19 was successful and it now aims to start phase III trials.

The statement read: "With these data, the company will begin, in the next few days, conversations with the regulatory agencies to define the next phase III pivotal study for plitidepsin (Aplidin) in patients with COVID-19, who require hospitalization."

Note that the drug is approved in Australia for the treatment of multiple myeloma.

S&P 500 futures rebound to 3,500

Amid encouraging vaccine news and upbeat European earnings reports, the sentiment remains lifted and helps boost the recovery in the S&P 500 futures.

The futures tied to the S&P 500 index rallies 0.88% to trade at 3,493, recovering from Friday’s low of 3,461.25.

Author

Dhwani Mehta

FXStreet

Residing in Mumbai (India), Dhwani is a Senior Analyst and Manager of the Asian session at FXStreet. She has over 10 years of experience in analyzing and covering the global financial markets, with specialization in Forex and commodities markets.

USD/JPY keeps range above 160.00 after BoJ's rate hike

USD/JPY holds losses and maintains its range above 160.00 on Tuesday, following the release of the Bank of Japan monetary policy decision. The BoJ hiked the key rate by 25 bps to 1% as widely, providing little to no impetus to the Japanese Yen. The focus is now on the BoJ' Uchida's press conference.

AUD/USD turns south toward 0.7050, with all eyes on RBA verdict

AUID/USD has come under renewed selling pressure and nears 0.7050 in Asia on Tuesday. Traders prefer to stay on the sidelines ahead of the Reserve Bank of Australia (RBA) monetary policy decision before placing fresh bets. Meanwhile, the mixed Chinese activity data failed to inspire the Aussie bulls amid fading US-Iran deal optimism.

$4,400: Gold sellers set to retain control whilst below this level; focus shifts to Fed

Gold holds a pullback from six-day highs of $4,369 as buyers take a breather early Tuesday. The US Dollar looks to fill Monday’s bearish opening gap as markets temper Iran deal optimism. Technically, Gold remains exposed to downside risks whilst below the 21-day SMA near $4,400.

Crypto Overview: Bitcoin weighs BOJ hikes interest rate to 1%, Uniswap and LayerZero sustain

Bitcoin is holding above $65,000 at press time on Tuesday as the Bank of Japan (BOJ) raises its interest rate to 1%, shifting focus away from the US-Iran peace agreement. Uniswap (UNI) and LayerZero edge lower on Tuesday but outpace the broader market over the last 24 hours as the retail sentiment recovers.

Kevin Warsh opens first Fed meeting June 16 with rate hold expected

Kevin Warsh was confirmed by the Senate in a 54-45 vote and sworn in as Federal Reserve Chair on 22 May 2026. The ceremony took place at the White House, with Supreme Court Justice Clarence Thomas administering the oath. The FOMC meeting on 16 and 17 June is his first as chair. The June meeting is also a quarterly projection meeting.

4.2% headline, 0.2% core: Why the Fed's next hike may be targeting the wrong problem

May's CPI put headline inflation at 4.2% on the year, up from 3.8% in April and the hottest reading since April 2023, while core prices rose just 0.2% on the month, undershooting the 0.3% consensus and halving April's pace.